The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2024 | Long-term outcomes of the OCEAN study: melflufen is superior to pomalidomide in R/R myeloma
Fredrik Hellem Schjesvold, MD, PhD, Oslo University Hospital, Oslo, Norway, discusses the long-term outcomes of the Phase III OCEAN trial (NCT03151811), comparing the efficacy of melflufen plus dexamethasone versus pomalidomide plus dexamethasone in relapsed/refractory (R/R) multiple myeloma (MM). Findings reveal superior progression-free survival (PFS) in patients treated with melflufen, with no new safety issues. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria for lectures and educational material: Skylite DX, Schain, Novartis, Janssen-Cilag, Takeda, Pfizer, Oncopeptides, Amgen, Sanofi, Bristol Myers Squibb, Daiichi Sankyo, Celgene, GlaxoSmithKline, Abbvie
Consultancy: Janssen-Cilag, Takeda, Oncopeptides, Sanofi, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Abbvie
Research Funding: Janssen-Cilag, Oncopeptides, Sanofi, Targovax, Celgene, GlaxoSmithKline
